Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
QuintilesIMS
Chubb
Colorcon
Johnson and Johnson

Generated: April 22, 2019

DrugPatentWatch Database Preview

CYCLOSET Drug Profile

« Back to Dashboard

Which patents cover Cycloset, and when can generic versions of Cycloset launch?

Cycloset is a drug marketed by Veroscience and is included in one NDA. There are thirteen patents protecting this drug.

This drug has twenty-five patent family members in thirteen countries.

The generic ingredient in CYCLOSET is bromocriptine mesylate. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

Drug patent expirations by year for CYCLOSET
Pharmacology for CYCLOSET
Medical Subject Heading (MeSH) Categories for CYCLOSET
Synonyms for CYCLOSET
.alpha.-Ergocryptine, methanesulfonate
(+)-Bromocriptine methanesulfonate
(5 inverted exclamation mark |A)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione Methanesulfonate
(5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione mesylate
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman methanesulfonate
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman methanesulfonate (salt)
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate
(5xi,5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman methanesulfonate (salt)
(5xi,5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate (salt)
(6aR,9R)-5-Bromo-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quin
2-Bromine-alpha-ergocryptine methanesulfonate
2-Bromo |A-Ergocryptine Mesylate
2-Bromo alpha-Ergocryptine Mesylate
2-Bromo-.alpha.-ergocryptine monomethanesulfonate
2-Bromo-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate
2-Bromo-a-ergocryptine methanesulfonate salt
2-Bromo-alpha-ergocryptine mesylate
2-Bromo-alpha-ergocryptine methanesulfonate
2-Bromo-alpha-ergokryptine-mesilate
2-Bromo-alpha-ergokryptine-mesilate [German]
2-Bromoergocryptine
2-Bromoergocryptine Mesylate
2-Bromoergocryptine monomethanesulfonate (salt)
22260-51-1
25614-03-3 (Parent)
93201-EP2272825A2
93201-EP2305633A1
AC1L1KXP
AKOS015896276
alpha-Ergocryptine, 2-bromo-, methanesulfonate
AN-17214
B 2134
B6298
Bagren
Bromergon
Bromocriptine (mesylate)
Bromocriptine mesilate
Bromocriptine mesilate (JP17)
BROMOCRIPTINE MESYLATE
Bromocriptine mesylate (USP)
Bromocriptine mesylate [USAN:USP]
Bromocriptine mesylate [USAN]
Bromocriptine methanesulfonate
Bromocryptine mesylate
Bromocryptine methanesulfonate
C32H40BrN5O5.CH4O3S
CAS-22260-51-1
CB 154
CB 154 methanesulfonate (salt)
CB-154
CB-154 mesylate
CCG-220121
CCG-221475
CHEBI:3182
CHEMBL1200503
CS-6048
D00780
DSSTox_CID_197
DSSTox_GSID_20197
DSSTox_RID_75426
DTXSID6020197
EINECS 244-881-1
Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-
EU-0100171
FFP983J3OD
HMS1568I04
HMS3260D03
HMS3712I04
HY-12705A
I06-2158
LP00171
LS-7234
MolPort-006-123-738
NCGC00257268-01
NCGC00260856-01
NOJMTMIRQRDZMT-GSPXQYRGSA-N
NSC-169774
NSC169774
oline-9-carboxamide methanesulfonate
Parlodel
Parlodel (TN)
Pravidel
Prestwick_771
SCHEMBL40559
SR-01000075356
SR-01000075356-1
SR-01000597796
SR-01000597796-1
SR-01000597796-2
Tox21_303597
Tox21_500171
UNII-FFP983J3OD

US Patents and Regulatory Information for CYCLOSET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for CYCLOSET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
McKinsey
Moodys
AstraZeneca
Queensland Health
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.